A Crack in the Window

Biotech investors are back. Sort of.

It’s official: the biotech industry is on the cusp of a financing boomlet. Through early October, the Amex Biotechnology Index was up 50% from its 2003 low of 311.69 in March. Investors have poured more than $10 billion into public biotech firms this year by way of convertible and secondary offerings. And between August and October, 12 biotech companies filed to go public, in anticipation of an open window for initial public offerings in the fourth quarter.

News Analysis

China’s Soy Ploy

» A Crack in the Window

Give Me Your Patents and Your Poor

Surprise, Surprise

Show and Tell

Waiting to Exhale

The Latest in Bioterrorism

Briefly Noted